OrganoPlate is MIMETAS' flagship organ-on-a-chip platform, supporting 3D cell culture under continuous perfusion for permeability, transport, migration, and co-culture assays without filter membranes. The microfluidic chip enables high-throughput, physiologically relevant human tissue and disease models used across pharmaceutical research.
Launched as the world's first mass-produced, quality-controlled organ-on-a-chip platform, OrganoPlate underpins MIMETAS' contract research services and Assay Ready product lines for ADME, safety, and toxicology studies.

OrganoPlate is a mass-produced organ-on-a-chip microfluidic platform for 3D human tissue and disease modeling in drug discovery.


High-throughput Organ-Chip instrument capable of running 96 Organ-Chip samples per run.


iPSC-derived Organ-Chip model of the human neurovascular unit for neurological drug development.


Emulate Organ-Chip Platform is an organ-on-a-chip system for human-relevant preclinical drug testing.


Benchtop Organ-Chip culture instrument that maintains up to 12 Organ-Chips under controlled flow and stretch.
High-throughput Organ-Chip instrument capable of running 96 Organ-Chip samples per run.

iPSC-derived Organ-Chip model of the human neurovascular unit for neurological drug development.

Emulate Organ-Chip Platform is an organ-on-a-chip system for human-relevant preclinical drug testing.

Benchtop Organ-Chip culture instrument that maintains up to 12 Organ-Chips under controlled flow and stretch.



Nortis ParVivo Platform is an organ-on-chip system for preclinical drug toxicity screening.


PhysioMimix is CN Bio's organ-on-a-chip microphysiological system for preclinical drug discovery.


Patient-Derived Organoid Platform is the primary commercial offering marketed by Xilis to its core customer segments.
Nortis ParVivo Platform is an organ-on-chip system for preclinical drug toxicity screening.

PhysioMimix is CN Bio's organ-on-a-chip microphysiological system for preclinical drug discovery.

Patient-Derived Organoid Platform is the primary commercial offering marketed by Xilis to its core customer segments.
